Australian (ASIC) OTC Derivatives Reporting: Preparing for March 2027

With around six months until the proposed March 2027 changes under Australian (ASIC) OTC derivatives reporting, now is the time for firms to understand what is changing, assess their readiness and consider the potential impact on their reporting model. Whether you already report under ASIC or are assessing whether the regime applies to your firm, the changes could affect your reporting obligations, controls and operating model. Discussion points What brings firms into scope today? How ASIC reporting obligations apply and the key factors firms should consider when assessing their reporting requirements. Including intercompany, cross-border and delegated reporting What is changing in March 2027? An overview of the upcoming changes and their potential impact. What is the implementation timeline? Key dates, readiness considerations and what firms should be testing now. What can firms learn from recent ASIC enforcement and fines? Understand the reporting weaknesses ASIC has focused on, including data quality, controls and governance, and what firms should be reviewing ahead of March 2027. How should firms prepare? Multi-jurisdictional reporting, integration options and practical considerations ahead of March 2027. Could delegated reporting also support broader trading relationships? Explore how offering reporting on behalf of clients or counterparties can reduce operational barriers and support relationships in Australia and across global markets. The session is designed for trading, treasury, compliance, regulatory reporting, operations, legal and technology teams, as well as firms assessing or expanding their trading activity in Australia. Attendees will leave with a clearer understanding of their potential obligations, the changes ahead and the practical steps required to strengthen reporting controls before implementation becomes time-critical.